ProQR Therapeutics

(NASDAQ) PRQR

Current Price$1.65

Market Cap$171.74M

Since IPO (2014)-89%

5 Year-72%

1 Year-9%

1 Month-5%

ProQR Therapeutics Financials at a Glance

Market Cap

$171.74M

Revenue (TTM)

$15.90M

Net Income (TTM)

$42.10M

EPS (TTM)

$-0.45

P/E Ratio

-3.58

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$1.65

Volume

13,098

Open

$1.68

Price

$1.65

Volume

13,098

Open

$1.68

Previous Close

$1.65

Daily Range

$1.59 - $1.69

52-Week Range

$1.33 - $3.10

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$1.65

Volume

13,098

Open

$1.68

Previous Close

$1.65

Daily Range

$1.59 - $1.69

52-Week Range

$1.33 - $3.10

PRQR News

optometrist covering her patient’s eyes with an occluder during an eye exam

Page 1

PRQR: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ProQR Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

186.6

CEO

Daniel Anton de Boer

Website

www.proqr-tx.com

Headquarters

Leiden, 2333 Ck, NL

PRQR Financials

Key Financial Metrics (TTM)

Gross Margin

96%

Operating Margin

-3%

Net Income Margin

-3%

Return on Equity

-64%

Return on Capital

-54%

Return on Assets

-37%

Earnings Yield

-27.93%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$171.74M

Shares Outstanding

105.36M

Volume

13.10K

Avg. Volume

530.84K

Financials (TTM)

Gross Profit

$12.68M

Operating Income

$42.15M

EBITDA

$39.56M

Operating Cash Flow

$50.71M

Capital Expenditure

$979.75K

Free Cash Flow

$51.69M

Cash & ST Invst.

$92.37M

Total Debt

$13.99M

ProQR Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$4.64M

+7.8%

Gross Profit

$3.97M

-7.8%

Gross Margin

85.52%

N/A

Market Cap

$171.74M

N/A

Market Cap/Employee

$1.03M

N/A

Employees

166

N/A

Net Income

$8.84M

+5.0%

EBITDA

$8.37M

-43.7%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$78.39M

-40.7%

Accounts Receivable

$5.08M

N/A

Inventory

$0.00

N/A

Long Term Debt

$9.54M

-13.8%

Short Term Debt

$4.44M

-27.8%

Return on Assets

-37.35%

N/A

Return on Invested Capital

-54.05%

N/A

Free Cash Flow

$13.59M

-43.4%

Operating Cash Flow

$13.07M

-39.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ARCTArcturus Therapeutics Holdings Inc.

ARCTArcturus Therapeutics Holdings Inc.$8.41-1.87%

ACHVAchieve Life Sciences, Inc.

ACHVAchieve Life Sciences, Inc.$4.56+3.87%

IMMPImmutep Limited

IMMPImmutep Limited$0.46-0.35%

EDITEditas Medicine, Inc.

EDITEditas Medicine, Inc.$3.04+1.33%

MREOMereo BioPharma Group plc

MREOMereo BioPharma Group plc$0.28-2.93%

ZURAZura Bio Limited

ZURAZura Bio Limited$5.18-2.63%

VNDAVanda Pharmaceuticals Inc.

VNDAVanda Pharmaceuticals Inc.$7.39-2.25%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$108.17+0.13%

NVDANvidia

NVDANvidia$196.45-0.01%

PINSPinterest

PINSPinterest$22.39+0.07%

PLTRPalantir Technologies

PLTRPalantir Technologies$136.03-0.07%

CIFRCipher Mining

CIFRCipher Mining$22.14+0.24%

POETPoet Technologies

POETPoet Technologies$9.23+0.30%

MUMicron Technology

MUMicron Technology$639.57+0.11%

Questions About PRQR

What is the current price of ProQR Therapeutics?

ProQR Therapeutics is trading at $1.65 per share.

What is the 52-week range for ProQR Therapeutics?

Over the past 52 weeks, ProQR Therapeutics has traded between $1.33 and $3.10.

How much debt does ProQR Therapeutics have?

As of the most recent reporting period, ProQR Therapeutics reported total debt of $16.43M.

How much cash does ProQR Therapeutics have on hand?

ProQR Therapeutics reported $108.53M in cash and cash equivalents in its most recent financial results.

What is ProQR Therapeutics’s dividend yield?

ProQR Therapeutics does not currently have a dividend yield.

ProQR Therapeutics

ProQR Therapeutics Financials at a Glance

PRQR News

Why Shares of ProQR Therapeutics Dropped on Wednesday

Why ProQR Therapeutics Stock Got Slammed Again Monday

Why ProQR Therapeutics Is Crashing Today

Here's Why ProQR Stock Surged on Thursday

An End to This Rare Syndrome Could Be an Opportunity for Investors

Why ProQR Therapeutics Stock Is Popping Today

Why ProQR Therapeutics N.V. Is Soaring Again Today

3 Biotech Stocks That Soared This Week: Are They Buys?

PRQR: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About ProQR Therapeutics

PRQR Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

ProQR Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PRQR

What is the current price of ProQR Therapeutics?

What is the 52-week range for ProQR Therapeutics?

How much debt does ProQR Therapeutics have?

How much cash does ProQR Therapeutics have on hand?

What is ProQR Therapeutics’s dividend yield?

Premium Investing Services